Malaga

• Clinical Study of Fianlimab in Combination With Cemiplimab versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated U … Ended recruitment
  2023-505772-30-00 5 2022-11-09 Melanoma
• Study of pembrolizumab, lenvatinib and chemotherapy combination in first line lung cancer Ended recruitment
  2024-511412-25-00 4 2022-11-07 First line treatment for extensive-stage small cell lung cancer small
• A study into the efficacy and safety of dazucorilant (CORT113176) in patients with Amyotrophic Lateral Sclerosis Ended recruitment
  2024-514082-19-00 4 2022-11-04 Amyotrophic Lateral Sclerosis
• Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended recruitment
  2024-517008-12-00 5 2022-10-14 Newly-diagnosed multiple myeloma (NDMM)
• A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin … Ended recruitment
  2023-503467-41-00 5 2022-10-12 Relapsed or Refractory Multiple Myeloma
• I-DXd in Patients With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Ended recruitment
  2024-512368-79-00 4 2022-10-10 Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC)
• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended recruitment
  2023-509429-37-00 5 2022-10-03 Advanced or Metastatic Non-Small Cell Lung Cancer
• Master Protocol for Encorafenib/Binimetinib Continuation Sub-Studies (FLOTILLA Study) Ended recruitment
  2023-509408-13-00 6 2022-09-20 Solid tumors
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously U … Ended recruitment
  2023-504194-21-00 5 2022-09-13 PD-L1 Positive Metastatic Triple-Negative Breast Cancer
• Phase 3 Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGF … Ended recruitment
  2023-507964-38-00 5 2022-09-01 Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutate
• Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable … Ended recruitment
  2023-504195-14-00 5 2022-08-31 PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
• Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic Alterations Ended recruitment
  2023-507933-12-00 5 2022-08-18 Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
• Taletrectinib in ROS1 Positive Lung Cancer Phase 2 Global Study Ended recruitment
  2024-516604-41-00 4 2022-08-08 Non-small Cell Lung Cancer
• A study to learn if Rozanolixizumab works and is safe over a long period in adults with relapsing myelin oligodendrocyte glycoprotein antibo … Ended recruitment
  2023-509237-39-00 5 2022-08-02 Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-A
• A trial to learn how well capivasertib with docetaxel works and how safe it is in people with metastatic castration-resistant prostate cance … Ended recruitment
  2023-504996-26-00 5 2022-07-21 Metastatic Castration Resistant Prostate Cancer (mCRPC)
• A trial to learn how well Dato-DXd works and how safe it is compared to standard chemotherapy in adults with triple-negative breast cancer ( … Ended recruitment
  2023-509260-25-00 5 2022-07-12 Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
• A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu … Ended recruitment
  2022-500014-26-00 5 2022-06-24 Locally-Advanced unresectable or Metastatic breast cancer (MBC)
• A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanc … Ended recruitment
  2024-512378-91-00 4 2022-06-24 Unresectable or Advanced Melanoma
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended recruitment
  2023-505974-14-00 5 2022-06-23 Multiple Sclerosis (MS)
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509345-12-00 5 2022-06-22 Multiple Sclerosis
• A clinical study that compares a treatment with Iberdomide, Daratumumab and Dexamethasone against a treatment with Daratumumab, Bortezomib, … Ended recruitment
  2024-510800-35-00 5 2022-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• Study of setmelanotide in patients with obesity with specific genetic variants Ended recruitment
  2023-507634-24-00 5 2022-05-20 Improper function of certain messenger materials in the body that cont
• A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce … Ended recruitment
  2023-509943-28-00 5 2022-05-18 Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (
• A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended recruitment
  2023-507795-51-00 5 2022-05-17 atherosclerotic heart and blood vessel disease (the narrowing of arter

Showing 649–672 of 1,048 trials